南方医科大学学报

南方医科大学学报 ›› 2016, Vol. 36 ›› Issue (09): 1303-.

• • 上一篇    

IFN-α 2b治疗1年疗效欠佳慢性乙型肝炎患者换用恩替卡韦7年后引发HBsAg血清学转换1 例

李桃源，陈友鹏   

  • 出版日期:2016-09-20 发布日期:2016-09-20

HBsAg seroconversion after entecavir therapy for 7 years following a poor response to interferon-α 2b monotherapy in a HBeAg-negative patient with chronic hepatitis B

  • Online:2016-09-20 Published:2016-09-20

HTML

PDF

1964

摘要： 恩替卡韦（ETV）是一种单磷酸腺苷的戊环核苷类似物，用于慢性乙型肝炎（CHB）患者抗病毒治疗。临床上较少报道 长期使用ETV治疗获得HBsAg 血清学转换。本例患者，男性，48 岁，诊断为HBeAg 阴性CHB，经普通干扰素治疗48 周后 HBV DNA仍可测，肝功能反复异常，序贯ETV治疗后，血清HBV DNA持续阴性以及ALT持续正常，并且治疗7 年后出现血 清HBsAg消失而且发生血清学转换。

Abstract: We report a rare case of HBsAg seroconversion after 7 years of entecavir therapy in a 48-year-old HBeAg-negative CHB male patient with chronic hepatitis B (CHB). After a poor response to a 48-week interferon-α 2b therapy, the patient received long-term entecavir therapy. Serum ALT levels became normal and HBV DNA viral load was undetectable at the 10th week after commencement of entecavir treatment, and seroconversion of HBsAg was detected after 7 years of entecavir therapy.